Mirum Pharmaceuticals, Inc. (MIRM) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

22/25

Growth 5 Margin 5 Expansion 4 Platform 3 Financial 5

latest quarter score

Earnings Reports

22
Merus Pharmaceuticals (MIRM) Q2 2026: Cash Climbs $170M on Commercial Execution, PSC Filing Delayed
August 06, 2026
23
Merum Pharmaceuticals (MIRM) Q1 2026: Rare Disease Platform Expands With $200M Global FOP Opportunity
May 07, 2026
17
MIRM Q4 2025: Net Product Sales Jump 55% as Four Registrational Readouts Approach
February 26, 2026
23
Mirim (MIRM) Q3 2025: Livmarli Drives 47% Revenue Growth as Pipeline Milestones Approach
November 05, 2025
20
Mirum Pharmaceuticals (MIRM) Q2 2025: 64% Revenue Surge Driven by Livmarli Expansion and Pipeline Momentum
August 06, 2025
21
MIRUM (MIRM) Q1 2025: Livmarli Tablet Approval and 61% Revenue Growth Signal Rare Disease Leadership
July 04, 2025

Browse all companies